Review Article

Is PPAR\(\beta/\delta\) a Retinoid Receptor?

Daniel C. Berry and Noa Noy

Department of Pharmacology, Case Western Reserve University School of Medicine, 10900 Euclid Ave., Cleveland, OH 44106, USA

Correspondence should be addressed to Noa Noy, noa.noy@case.edu

Received 11 June 2007; Accepted 21 November 2007

Recommended by John P. Vanden Heuvel

The broad ligand-binding characteristic of PPAR\(\beta/\delta\) has long hampered identification of physiologically-meaningful ligands for the receptor. The observations that the activity of PPAR\(\beta/\delta\) is supported by fatty acid binding protein 5 (FABP5), which directly delivers ligands from the cytosol to the receptor, suggest that bona fide PPAR\(\beta/\delta\) ligands both activate the receptor, and trigger the nuclear translocation of FABP5. Using these criteria, it was recently demonstrated that all-trans-retinoic acid (RA), the activator of the classical retinoic acid receptor RAR, also serves as a ligand for PPAR\(\beta/\delta\). Partitioning of RA between its two receptors was found to be regulated by FABP5, which delivers it to PPAR\(\beta/\delta\), and cellular RA binding protein II (CRABP-II), which targets it to RAR. Consequently, RA activates PPAR\(\beta/\delta\) in cells that display a high FABP5/CRABP-II expression ratio. It remains to be clarified whether compounds other than RA may also serve as endogenous activators for this highly promiscuous protein.

Copyright © 2007 D. C. Berry and N. Noy. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

Peroxisome proliferator-activated receptors (PPARs), the “lipid sensors,” are activated by fatty acids and various fatty acid derivatives to regulate the expression of genes involved in multiple physiological functions. Like other members of subclass 1 of the superfamily of nuclear hormone receptors, PPARs interact with the retinoid X receptor (RXR) to form heterodimers that bind to PPAR response elements (PPRE) in regulatory regions of specific target genes [1]. Binding of cognate ligands to these heterodimers results in receptor activation and in upregulation of target gene transcription [2–5]. Three PPAR subtypes, encoded for by three separate genes, are known to exist: PPAR\(\alpha\), PPAR\(\beta/\delta\), and PPAR\(\gamma\) [6]. PPAR\(\alpha\) is expressed in liver, heart, muscle, and kidney, where it regulates fatty acid catabolism. Consequently, activation of PPAR\(\alpha\) lowers serum lipid levels; and synthetic ligands for this receptor are efficient therapeutic agents in treatment of hyperlipidemia [7, 8]. PPAR\(\gamma\) is expressed predominantly in adipose tissue and macrophages, where it is involved in adipocyte differentiation, regulation of sugar and lipid homeostasis, and control of inflammatory responses [9, 10]. Thiazolidinediones, synthetic compounds that activate PPAR\(\gamma\), are in current use as antidiabetic drugs [11]. Several biological lipids have been suggested to serve as endogenous ligands for PPARs. Thus, it was reported that PPAR\(\alpha\) can be activated by 8(S)-HETE and by leukotriene B4 (LTB4) [12, 13]. It was also suggested that the arachidonic acid metabolite 15 deoxy-delta 12,14 prostaglandin J2 (PGJ2) functions as an endogenous ligand for PPAR\(\gamma\) [14]. However, the involvement of these and other potential ligands in the activities of PPARs in vivo has not been established, and these receptors remain classified as “orphan receptors.”

PPAR\(\beta/\delta\) is ubiquitously expressed with particularly high level of expression found in brain, adipose tissue, skeletal muscle, and skin [15]. This receptor is involved in neuronal development [16], inflammation [17–19], skeletal muscle lipid oxidation [20], keratinocyte differentiation, epidermal barrier recovery, and lipid synthesis for keratinocyte proliferation [21, 22]. PPAR\(\beta/\delta\) expression in skin is increased in hyperproliferative lesions, and in response to inflammatory cytokines during skin injury [18, 19]. Elevation of PPAR\(\beta/\delta\) expression in keratinocytes during skin injury is accompanied by production of an (unknown) endogenous ligand(s), resulting in protection against apoptotic signals and in enhancement of skin repair [18]. These antiapoptotic activities are mediated, at least in part, by the ability of PPAR\(\beta/\delta\) to directly upregulate the expression of PDK1, thereby activating the survival factor Akt1 and protecting keratinocytes from apoptosis induced by cytokines such as TNF\(\alpha\) [19, 21, 23, 24].
PPARβ/δ is the primary PPAR isotype in skeletal muscle [25] where it plays a role in fiber formation and maintenance [20] and enhances fatty acid oxidation and mitochondrial respiration [26].

Importantly, it has been reported that PPARβ/δ is involved in regulating lipid and sugar homeostasis and that activation of the receptor results in protection against adiposity and insulin resistance. These activities appear to stem from transcriptional regulation of various genes, including uncoupling proteins 1 and 3, long-chain and very-long-chain acyl CoA synthetase, and muscle carnitine palmitoyltransferase-1, resulting in depletion of adipose lipid storage and in decreased levels of circulating triglycerides and free fatty acids [26]. In macrophages, activation of PPARβ/δ increases expression of ALDH9, a gene involved in carnitine biosynthesis, and leads to lipid mobilization and increased fatty acid catabolism [27]. It was also demonstrated that treatment with a selective PPARβ/δ ligand leads to improvement in hepatic glucose output, higher glucose disposal, and inhibition of free fatty acid release from adipocytes [26]. Protective activities of PPARβ/δ against insulin resistance may also be mediated by the direct target gene PDK1, which is involved in mobilization of the insulin-responsive glucose transporter GLUT4 to the plasma membrane [28].

2. PROPOSED LIGANDS FOR PPARβ/δ

Like other PPARs, the nature of endogenous, physiologically-meaningful ligands for PPARβ/δ has long remained unknown. The ligand-binding pocket of this receptor is considerably larger than other nuclear receptors displaying a total volume of ~1300 Å [29–31]. The pocket forms a “Y” shape comprised of three arms approximately 12 Å in length [30, 31]. A solvent-exposed channel allows accessibility into the ligand binding pocket with an entrance area of approximately 100 Å2 with the ability to open even larger due to the flexibility in surrounding helices [30]. The extensive size of the pocket is consistent with the promiscuous ligand binding displayed by the receptor; and raises the possibility that it may be activated by multiple compounds. Examination of X-ray crystal structures of bacterially expressed PPARβ/δ ligand-binding domain revealed that the protein was bound by fatty acids such as eicosapentaenoic acid (EPA) [30], 11,Z-octadecenoic acid [31], palmitic acid, and stearic acid [31]. It is worth noting however that, while multiple fatty acid derivatives can bind to this receptor, not all of these function as activators. Biological compounds that were reported to activate PPARβ/δ include various leukotrienes and prostaglandins, such as prostaglandin A1, iloprost, PG15d-J2, and carboxyprostacyclin [32, 33].

3. RETINOIC ACID IS A LIGAND FOR PPARβ/δ

Recent observations suggested that PPARβ/δ is activated by an unexpected fatty acid, the vitamin A metabolite all-trans-retinoic acid (RA) (see Figure 1). It was thus reported that RA binds to PPARβ/δ with a Kd of ~15 nM, displaying an order of magnitude higher affinity for this subtype as compared to its affinity towards PPARα and PPARγ [34]. It may be worth noting that the binding affinity for RA towards PPARβ/δ is over an order of magnitude weaker than the affinity of RAR towards this ligand, which was reported to be in the sub-nM range [35]. Nevertheless, RA enhances the ability of PPARβ/δ, but not other PPAR isotypes, to induce the expression of a reporter gene driven by a PPRE [34], suggesting that it functions as a selective PPARβ/δ ligand.

RA plays key roles both during embryonic development and in adult tissue, where it is involved in regulation of cellular metabolism, proliferation, differentiation, and apoptosis. It is well established that many of the pleiotropic activities of RA are exerted primarily through its ability to regulate gene expression, and are mediated by the nuclear hormone receptors termed retinoic acid receptors (RARs) [36, 37]. Like PPARs, RARs heterodimerizes with RXR, the complex binds to RAR response elements (RAREs) in regulatory regions of target genes, and it enhances transcriptional rates upon ligand-induced activation. In this fashion, RA also displays distinct anticarcinogenic activities mediated by RAR-induced upregulation of genes involved in cell cycle arrest [38], differentiation [39, 40], and apoptosis [41–43].

The observations that, in addition to activating RAR, RA also activates PPARβ/δ, raise the possibility that some of the biological activities of this hormone may be mediated by an RAR-independent pathway. An RAR-independent activity of RA has indeed been suggested by studies of RA functions in skin maintenance. Hence, while it is well established that RA is essential for skin maintenance [44, 45], it was reported that all RAR subtypes are dispensable for this activity [46]. In addition, while activation of RAR often results in inhibition of cell growth [47–49], various reports demonstrated that, in some cancers, this hormone induces carcinoma cell proliferation [50], again suggesting a mode of action that is mediated by a pathway other than activation of RAR. Taken together, the identification of RA as a potent ligand for PPARβ/δ, and the observations that this receptor can directly upregulate the expression of prosurvival and proliferative genes [24, 51] raise the intriguing possibility that “nonclassical” proliferative activities of RA may be mediated by PPARβ/δ.

Indeed, it was demonstrated that, in keratinocytes, RA functions as a bona fide PPARβ/δ-ligand to induce the expression of well-known PPARβ/δ-target genes including adipose differentiation-related protein (ADRP) [52], fasting-induced adipose factor (FIAF) [53], and PDK1 [24]. As expression of these genes was found to be induced by RA and by a selective synthetic PPARβ/δ-ligand, but not by an RAR-selective ligand [54], the data strongly supported the conclusion that these activities of RA in keratinocytes are mediated by PPARβ/δ and not by the classical RA receptor RAR. An
important question raised by these observations relates to the mechanism by which partitioning of RA between the two receptors may be regulated, that is, what underlies the ability of the hormone to activate RAR in some cells but to target PPARβ/δ in others?

4. **RA IS DELIVERED TO PPARβ/δ BY FATTY ACID-BINDING PROTEIN 5**

In addition to associating with nuclear receptors, many hydrophobic compounds bind in cells to members of the family of intracellular lipid binding proteins (iLBPs). It has been demonstrated that some iLBPs cooperate with some nuclear receptors in mediating the transcriptional activities of their common ligands [51, 55–58]. For example, it was shown that the iLBP termed cellular retinoic acid binding protein II (CRABP-II) serves to directly deliver RA from the cytosol to the nucleus where it binds to RAR to form a complex that mediates direct “channeling” of the hormone from the binding protein to the receptor. It was demonstrated further that, by directly delivering RA to RAR, CRABP-II significantly enhances the transcriptional activity of the receptor, and dramatically sensitzes cells to RA-induced, RAR-mediated biological activities [56, 59].

In addition to CRABP-II, the iLBP family also includes nine isoforms of fatty acid binding proteins. FABPs are more promiscuous than CRABPs and they bind a variety of fatty acids and fatty acid derivatives [51, 60, 61] displaying ligand-binding selectivities reminiscent of those of PPARs. One FABP, termed FABP5 (K-FABP, mal1, eFABP), was found to cooperate with PPARβ/δ in a manner similar to that found for the cooperation of CRABP-II with RAR. Specifically, it was shown that, upon binding of PPARβ/δ-activators, FABP5 mobilizes from the cytosol to the nucleus, and that it delivers the ligand to its cognate receptor through direct interactions, thereby significantly augmenting the transcriptional activity of the receptor [51, 54]. Remarkably, while FABP5 binds various ligands with similar affinities, it mobilizes to the nucleus only in response to specific compounds [51, 54]. Hence, PPARβ/δ activators display two distinct functions: they activate the receptor, and they trigger the nuclear import of the PPARβ/δ-associated iLBP, FABP5. The observations that RA not only induces the transcriptional activity of PPARβ/δ but also activates the nuclear translocation of FABP5 [54] raise the level of confidence that this ligand, indeed, functions as a physiologically meaningful activator for the receptor. It should be noted that, in the context of reporter gene assays, RA may activate both RAR and PPARβ/δ in the absence of their cognate binding proteins if present at high enough concentrations, but that activation at low concentrations is significantly augmented by the respective binding proteins (see, e.g., [56]). These observations suggest that the binding proteins are necessary for efficient receptor activation under physiological concentrations of their ligands in vivo.

Available information thus indicates that RA alternatively activates two different nuclear receptors: RAR and PPARβ/δ, and that the partitioning of this hormone between these receptors is regulated by two iLBPs that selectively cooperate with these receptors, CRABP-II, which delivers RA to RAR, and FABP5, which “channels” RA to PPARβ/δ. Hence, the relative expression levels of the two binding proteins in different cells will determine the spectrum of genes that can be activated in response to RA, and thus the RA-induced cellular responses. Interestingly, it has been demonstrated that, in the context of two cell types, keratinocytes and MCF-7 mammary carcinoma cells, and in tumors that arise in vivo in the mammary carcinoma mouse model MMTVneu, alternate activation of the two receptors lead to opposing biological responses: RA-induced activation of the CRABP-II/RAR pathway results in inhibition of cell growth, while activation of FABP5/PPARβ/δ enhances proliferation and enables cell survival in the face of potent apoptotic agents [54, 59].

5. **CONCLUSIONS**

The involvement of PPARβ/δ in regulation of keratinocyte proliferation, skeletal muscle metabolism, inflammation, and lipid homeostasis, together with the recent suggestions that this receptor may be a target for therapeutic strategies in treatment of the metabolic syndrome, emphasize the need for identification of ligands that activate this receptor in vivo. The extensive size of its ligand binding pocket and its broad ligand selectivity raise the possibility that PPARβ/δ may be activated by multiple compounds, and, perhaps, that different ligands serve in this function in different cells and/or under different physiological circumstances. The observations that efficient activation of this receptor requires cooperation with FABP5, which specifically delivers ligands from the cytosol to nuclear PPARβ/δ, provide a new powerful criterion for identifying physiologically-meaningful ligands. Hence, such ligands will be required not only to activate the receptor, but also to trigger the nuclear translocation of the binding protein. Using these criteria, it was recently demonstrated that RA is a potent endogenous ligand for PPARβ/δ. These observations suggest that PPARβ/δ is a retinoid receptor, functioning similarly to RAR and RXR to regulate gene expression in response to a vitamin A metabolite. The question of whether RA is the sole endogenous ligand for this receptor or whether additional physiologically-meaningful ligands exist remains open and awaits further studies.

**ACKNOWLEDGMENTS**

Research in the author’s laboratory has been supported by Grants no. CA68150 and no. CA107013 from the National Cancer Institute, no. DK60684 from the National Institute of Diabetes and Digestive and Kidney Diseases, and no. BCTR27606 from The Susan G. Komen Breast Cancer Foundation.

**REFERENCES**

[1] D. J. Mangelsdorf and R. M. Evans, “The RXR heterodimers and orphan receptors,” Cell, vol. 83, no. 6, pp. 841–850, 1995.
[2] V. Bocher, G. Chinetti, J. C. Fruchart, and B. Staels, “Role of the peroxisome proliferator-activated receptors (PPARs) in the regulation of lipids and inflammation control,” Journal de la Société de Biologie, vol. 196, no. 1, pp. 47–52, 2002.
V. Bocher, I. Pineda-Torra, J. C. Fruchtart, and B. Staels, “PPARs: transcription factors controlling lipid and lipoprotein metabolism,” *Annals of the New York Academy of Sciences*, vol. 967, pp. 7–18, 2002.

A. Chawla, J. J. Repa, R. M. Evans, and D. J. Mangelsdorf, “Nuclear receptors and lipid physiology: opening the X-files,” *Science*, vol. 294, no. 5548, pp. 1866–1870, 2001.

S. A. Smith, “Peroxisomal proliferate-activated receptors and the regulation of lipid oxidation and adipogenesis,” *Biochemical Society Transactions*, vol. 25, no. 4, pp. 1242–1248, 1997.

T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, “The PPARs: from orphan receptors to drug discovery,” *Journal of Medicinal Chemistry*, vol. 43, no. 4, pp. 527–550, 2000.

S. Mandand, M. Muller, and S. Kersten, “Peroxisome proliferator-activated receptor α target genes,” *Cellular and Molecular Life Sciences*, vol. 61, no. 4, pp. 393–416, 2004.

D. Duffy and D. J. Rader, “Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport,” *Current Opinion in Cardiology*, vol. 20, no. 4, pp. 301–306, 2005.

M. A. Lazar, “PPAR γ, 10 years later,” *Biochimie*, vol. 87, no. 1, pp. 9–13, 2005.

M. Lehrke and M. A. Lazar, “The many faces of PPAR γ,” *Cell*, vol. 123, no. 6, pp. 993–999, 2005.

J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkinson, T. M. Willson, and S. A. Kliewer, “An antidiabetetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ),” *Journal of Biological Chemistry*, vol. 270, no. 22, pp. 12953–12956, 1995.

B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” *Endocrine Reviews*, vol. 20, no. 5, pp. 649–688, 1999.

P. R. Devchand, H. Keller, J. M. Peters, M. Vazquez, F. J. Gonzalez, and W. Wahli, “The PPARα-leukotriene B4 pathway to inflammation control,” *Nature*, vol. 384, no. 6604, pp. 39–43, 1996.

B. M. Forman, E. Goode, J. Chen, et al., “Identification of a nuclear receptor that is activated by farnesol metabolites,” *Cell*, vol. 81, no. 5, pp. 687–693, 1995.

J. M. Peters, S. S. Lee, W. Li, et al., “Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ),” *Molecular and Cellular Biology*, vol. 20, no. 14, pp. 5119–5128, 2000.

A. G. Cimini, L. Cristiano, A. Bernardo, E. Benedetti, S. D. I. Loreto, and M. P. Ceru, “Peroxisomes and PPARs in cultured neural cells,” *Advances in Experimental Medicine and Biology*, vol. 544, pp. 271–280, 2003.

N. S. Tan, L. Michalik, B. Desvergne, and W. Wahli, “Peroxisome proliferator-activated receptor-β as a target for wound healing drugs,” *Expert Opinion on Therapeutic Targets*, vol. 8, no. 1, pp. 39–48, 2004.

N. S. Tan, L. Michalik, N. Noy, et al., “Critical roles of PPAR β/δ in keratinocyte response to inflammation,” *Genes & Development*, vol. 15, no. 24, pp. 3263–3277, 2001.

N. S. Tan, L. Michalik, N. Di-Poi, B. Desvergne, and W. Wahli, “Critical roles of the nuclear receptor PPARβ (peroxisome-proliferator-activated receptor β) in skin wound healing,” *Biochemical Society Transactions*, vol. 32, no. 1, pp. 97–102, 2004.

Y.-X. Wang, C.-L. Zhang, R. T. Yu, et al., “Regulation of muscle fiber type and running endurance by PPARβ,” *Plos Biology*, vol. 2, no. 10, p. e294, 2004.

G. Icee, W. Wahli, and L. Michalik, “Functions of the peroxisome proliferator-activated receptor (PPAR) α and β in skin homeostasis, epithelial repair, and morphogenesis,” *The Journal of Investigative Dermatology Symposium Proceedings*, vol. 11, no. 1, pp. 30–35, 2006.

L. Michalik and W. Wahli, “Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease,” *Biochimica et Biophysica Acta*, vol. 1771, no. 8, pp. 991–998, 2007.

A. D. Burdick, D. J. Kim, M. A. Peraza, F. J. Gonzalez, and J. M. Peters, “The role of peroxisome proliferator-activated receptor-β/δ in epithelial cell growth and differentiation,” *Cell Signal*, vol. 18, no. 1, pp. 9–20, 2006.

N. Di-Poi, N. S. Tan, L. Michalik, W. Wahli, and B. Desvergne, “Antiapoptotic role of PPARβ in keratinocytes via transcriptional control of the Akt1 signaling pathway,” *Molecular Cell*, vol. 10, no. 4, pp. 721–733, 2002.

O. Braissant, F. Fougelle, C. Scotto, M. Dauca, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPARα, -β, and -γ in the adult rat,” *Endocrinology*, vol. 137, no. 1, pp. 354–366, 1996.

Y. X. Wang, C. H. Lee, S. Tiep, et al., “Peroxisome proliferator-activated receptor δ activates fat metabolism to prevent obesity,” *Cell*, vol. 113, no. 2, pp. 159–70, 2003.

C. H. Lee, K. Kang, I. R. Muhl, et al., “Peroxisome proliferator-activated receptor δ promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 7, pp. 2434–2439, 2006.

T. Yamada, H. Katagiri, T. Asano, et al., “Role of PDK1 in insulin-signaling pathway for glucose metabolism in 3T3-L1 adipocytes,” *American Journal of Physiology. Endocrinology and Metabolism*, vol. 282, no. 6, pp. E1385–E1394, 2002.

R. T. Nolte, G. B. Wisely, S. Westin, et al., “Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ,” *Nature*, vol. 395, no. 6698, pp. 137–143, 1998.

H. E. Xu, M. H. Lambert, V. G. Montana, et al., “Molecular recognition of fatty acids by peroxisome proliferator-activated receptors,” *Molecular Cell*, vol. 3, no. 3, pp. 397–403, 1999.

S. A. Pytl, M. S. Alphay, L. Buetow, et al., “Recombinant human PPAR-β/δ ligand-binding domain is locked in an activated conformation by endogenous fatty acids,” *Journal of Molecular Biology*, vol. 356, no. 4, pp. 1005–1013, 2006.

S. Kersten and W. Wahli, “Peroxisome proliferator activated receptor agonists,” *EXS*, vol. 89, pp. 141–151, 2000.

B. M. Forman, J. Chen, and R. M. Evans, “Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 9, pp. 4312–4317, 1997.

N. Shaw, M. Elholm, and N. Noy, “Retinoic acid is a high affinity selective ligand for the peroxisome proliferator-activated receptor β/δ,” *Journal of Biological Chemistry*, vol. 278, no. 43, pp. 41589–41592, 2003.

E. Sussman and A. R. De Lera, “Ligand recognition by RAR and RXR receptors: binding and selectivity,” *Journal of Medicinal Chemistry*, vol. 48, no. 20, pp. 6212–6219, 2005.

P. Chambron, “A decade of molecular biology of retinoic acid receptors,” *FASEB Journal*, vol. 10, no. 9, pp. 940–954, 1996.

D. J. Mangelsdorf, “Vitamin A receptors,” *Nutrition Reviews*, vol. 52, no. 2 part 2, pp. 532–544, 1994.

L. J. Donato, J. H. Suh, and N. Noy, “Suppression of mammary carcinoma cell growth by retinoic acid: the cell cycle control gene Bg2 is a direct target for retinoic acid receptor signaling,” *Cancer Research*, vol. 67, no. 2, pp. 609–615, 2007.
[39] C. Rochette-Egly and P. Chambon, "F9 embryocarcinoma cells: a cell autonomous model to study the functional selectivity of RARs and RXRs in retinoid signaling," *Histology and Histopathology*, vol. 16, no. 3, pp. 909–922, 2001.

[40] D. J. Park, A. M. Chumakov, P. T. Viong, et al., “CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment,” *The Journal of Clinical Investigation*, vol. 103, no. 10, pp. 1399–1408, 1999.

[41] L. Altucci and H. Gronemeyer, “Nuclear receptors in cell life and death,” *Trends in Endocrinology and Metabolism*, vol. 12, no. 10, pp. 460–468, 2001.

[42] L. J. Donato and N. Noy, “Suppression of mammary carcinoma growth by retinoic acid: proapoptotic genes are targets for retinoic acid receptor and cellular retinoic acid-binding protein II signaling,” *Cancer Research*, vol. 65, no. 18, pp. 8193–8199, 2005.

[43] S. Kitareewan, I. Pitha-Rowe, D. Sekula, et al., “UBE1L is a retinoid target that triggers PML/RARα degradation and apoptosis in acute promyelocytic leukemia,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 6, pp. 3806–3811, 2002.

[44] S. B. Wolbach and P. R. Howe, “Nutrition Classics,” *The Journal of Experimental Medicine*, vol. 42, pp. 753–777, 1925.

[45] S. B. Wolbach and P. R. Howe, “Tissue changes following deprivation of fat-soluble A vitamin,” *Nutrition Reviews*, vol. 36, no. 1, pp. 16–19, 1978.

[46] B. Chapellier, M. Mark, N. Messaddeq, et al., “Physiological and retinoid-induced proliferations of epidermis basal keratinocytes are differentially controlled,” *EMBO Journal*, vol. 21, no. 13, pp. 3402–3413, 2002.

[47] Q. Le, M. I. Dawson, D. R. Soprano, and K. J. Soprano, “Modulation of retinoic acid receptor function alters the growth inhibitory response of oral SCC cells to retinoids,” *Oncogene*, vol. 19, no. 11, pp. 1457–1465, 2000.

[48] S. Wū, A. Donigan, C. D. Platsoucas, W. Jung, D. R. Soprano, and K. J. Soprano, "All-trans-retinoic acid blocks cell cycle progression of human ovarian adenocarcinoma cells at late G1," *Experimental Cell Research*, vol. 232, no. 2, pp. 277–286, 1997.

[49] S. Wū, D. Zhang, A. Donigan, M. I. Dawson, D. R. Soprano, and K. J. Soprano, “Effects of conformationally restricted synthetic retinoids on ovarian tumor cell growth,” *Journal of Cellular Biochemistry*, vol. 68, no. 3, pp. 378–388, 1998.

[50] A. K. Verma, E. A. Conrad, and R. K. Boutwell, “Differential effect of retinoic acid and 7,8-benzozlavone on the induction of mouse skin tumors by the complete carcinogenesis process and by the initiation-promotion regimen,” *Cancer Research*, vol. 42, no. 9, pp. 3519–3525, 1982.

[51] N.-S. Tan, N. S. Shaw, N. Vinckenbosch, et al., “Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription,” *Molecular and Cellular Biology*, vol. 22, no. 14, pp. 5114–5127, 2002.

[52] M. Schmuth, C. M. Haqq, W. J. Cairns, et al., “Peroxisome proliferator-activated receptor (PPAR)-β/δ stimulates differentiation and lipid accumulation in keratinocytes,” *Journal of Investigative Dermatology*, vol. 122, no. 4, pp. 971–983, 2004.

[53] S. Kersten, S. Mandard, N. S. Tan, et al., “Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene,” *Journal of Biological Chemistry*, vol. 275, no. 37, pp. 28488–28493, 2000.

[54] T. T. Schug, D. C. Berry, N. S. Shaw, S. N. Travis, and N. Noy, “Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors,” *Cell*, vol. 129, no. 4, pp. 723–733, 2007.

[55] A. S. Budhu, R. Gillilan, and N. Noy, “Localization of the RAR interaction domain of cellular retinoic acid binding protein-II,” *Journal of Molecular Biology*, vol. 305, no. 4, pp. 939–949, 2001.

[56] A. S. Budhu and N. Noy, “Direct channeling of retinoic acid between cellular retinoic acid-binding protein II and retinoic acid receptor sensitizes mammary carcinoma cells to retinoic acid-induced growth arrest,” *Molecular and Cellular Biology*, vol. 22, no. 8, pp. 2632–2641, 2002.

[57] D. Dong, S. E. Ruuska, D. J. Levinthal, and N. Noy, “Distinct roles for cellular retinoic acid-binding proteins I and II in regulating signaling by retinoic acid,” *Journal of Biological Chemistry*, vol. 274, no. 34, pp. 23695–23698, 1999.

[58] R. J. Sessler and N. Noy, “A ligand-activated nuclear localization signal in cellular retinoic acid binding protein-II,” *Molecular Cell*, vol. 18, no. 3, pp. 343–353, 2005.

[59] D. Manor, E. N. Shmidt, A. Budhu, et al., “Mammary carcinoma suppression by cellular retinoic acid binding protein–II,” *Cancer Research*, vol. 63, no. 15, pp. 4426–4433, 2003.

[60] L.H. Gutiérrez-González, C. Ludwig, C. Hoboff, et al., “Solution structure and backbone dynamics of human epidermal-type fatty acid-binding protein (E-FABP),” *Biochemical Journal*, vol. 364, no. 3, pp. 725–737, 2002.

[61] A. W. Norris and A. A. Spector, “Very long chain n-3 and n-6 polyunsaturated fatty acids bind strongly to liver fatty acid-binding protein,” *Journal of Lipid Research*, vol. 43, no. 4, pp. 646–653, 2002.